documents: FDA-2026-N-1867-0001
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2026-N-1867-0001 | FDA | FDA-2026-N-1867 | Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—New Drug Application 220359, for Camizestrant Tablets; Supplemental New Drug Application (sNDA) 218197/S–004, for Truqap (Capivasertib) Tablets | Notice | Request for Comments | 2026-03-09 | 2026 | 3 | 2026-03-09 | 2026-04-30 | 2026-04-16 09:00:12 | 2026-04497 | 1 | 0 | 09000064b9200842 |